Icon

ALUNBRIG (nda208772)- (30MG,90MG,180MG)

BRIGATINIB TAKEDA PHARMS USA
30MG,90MG,180MG
No No
2035-Nov-10 2022-Apr-28
2024-Apr-28 None
None No
ALUNBRIG is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
0 0 0
Total Other Developers 1
Drugs with Suitability No
30MG ** ** - - -
90MG ** ** - - -
180MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.